Urolithiasis
Conditions
Brief summary
as the supra eleventh puncture PCNL is not well investigated in the literature we will conduct that randomised trial in comparison to the subcostal one
Detailed description
The use of percutaneous nephrolithotomy (PCNL) was first reported by Fernström and Johansson in 1976. Percutaneous nephrolithotomy (PCNL) is the accepted treatment for staghorn stones, large renal stones, and some upper ureteric stones. Achieving suitable access to the appropriate calyx is one of the most important steps during the PCNL procedure. Effective puncture is key for the success of PCNL. An ideal percutaneous nephrolithotomy (PCNL) puncture has been described as one that provides the shortest and straightest access to all calculi, avoids major vessels, bowel and lung, lies along the axis of the calyx and causes minimal parenchymal damage. Many studies have reported that supracostal access for PCNL is advantageous over infracostal access. By creating a straight path along the kidney's long axis, the upper-pole method guarantees access to the majority of the collecting system and makes it simpler to manipulate the rigid nephroscope and other rigid devices. Therefore, supracostal puncture is perhaps the greatest method for gaining access to the upper pole calyx, where staghorn and big, complicated renal stones are most likely to be located. Although pneumothorax, hydrothorax, and lung damage (1-10%) can result after a supracostal puncture, this injury can now be handled with minimal morbidity thanks to advances in surgical technique and understanding of pleural and diaphragmatic architecture.
Interventions
percutaneous nephrolithotomy
Sponsors
Study design
Masking description
closed envelop
Eligibility
Inclusion criteria
* Age ≥ 18 years old. * Patients amenable for PCNL with stone burden between 2 cm - 4 cm (guy score 1-2-3)
Exclusion criteria
* Ectopic kidney. * Single middle calyceal stone. * Skeletal anomalies. * Bleeding diathesis. * Active urinary tract infection. * Patient refusing participation. * Patients with active pulmonary and pleural disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of complications | within 3 months post operative | Clavien -Dindo classification. |
| Stone free rate | within 3 months post operative | the patient being either completely stone-free or there are residual fragments (less than 4 mm). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| duration of Hospital stay. | Postoperativly | post operative hospital stay |
| Operative time | intraoperative | from the puncture until withdrawal of the endoscope at the end of the operation |
Countries
Egypt